Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of Signal of Clindamycin Associated Renal Failure Acute: A Disproportionality Analysis

Author(s): Faiza Javed and Anoop Kumar*

Volume 19, Issue 1, 2024

Published on: 05 April, 2023

Page: [123 - 128] Pages: 6

DOI: 10.2174/1574886318666230228142856

Price: $65

Abstract

Background: Early signal detection from post-marketing studies play a vital role in the safety of patients. Recent case reports have indicated the association of clindamycin with renal failure acute. However, renal failure acute is not known to be associated with clindamycin. The aim of the study was the identification of the potential signal of clindamycin-associated renal failure acute.

Methods: The OpenVigil 2.1-MedDRA-v24 was used to query the FAERS database. The Reporting Odds Ratio (ROR) with a 95% confidence interval, was used to assess the association between clindamycin and renal failure acute.

Results: A total of 22326 cases associated with renal failure acute were found in OpenVigil 2.1- MedDRA-v24. Among these 125 were associated with clindamycin. The ROR was found to be 3.2 (2.7, 3.8) which indicates a statistically significant association between clindamycin and renal failure acute reporting. The signal strength was decreased after removing the cases of concomitantly administered drugs, however, the association of clindamycin with renal failure acute reporting remains statistically significant. The subgroup analysis results have also shown a positive signal of clindamycin with renal failure acute.

Conclusion: The current study identified a positive signal of clindamycin as renal failure acute. However, further validation and causality assessment are required.

Keywords: Clindamycin, renal failure acute, OpenVigil 2.1, disproportionality analysis, signal detection, clindamycin-associated renal failure.

« Previous Next »
Graphical Abstract

[1]
World health organization. Quality Assurance and Safety of Medicines Team. Safety of Medicines. Aguide to delicting and report adverse durg reaction, Wht health professionals need to take action. WHO 2002.
[2]
Subeesh V, Singh H, Maheswari E, Beulah E. Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. Asian J Psychiatr 2017; 30: 152-6.
[http://dx.doi.org/10.1016/j.ajp.2017.09.005] [PMID: 28942181]
[3]
Sharma A, Kumar A. Identification of novel signal of clobazam‐associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis. Acta Neurol Scand 2022; 146(5): 623-7.
[http://dx.doi.org/10.1111/ane.13690] [PMID: 36029138]
[4]
Spížek J, Řezanka T. Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol 2004; 64(4): 455-64.
[http://dx.doi.org/10.1007/s00253-003-1545-7] [PMID: 14762701]
[5]
Summary of product characteristics (SmPC) of clindamycin. Electronic Medicines Compendium. Available from: https://www.medicines.org.uk/emc#gref [Accessed on: 30th Sep 2021].
[6]
Nakao S, Hasegawa S, Umetsu R, et al. Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database. BMC Pharmacol Toxicol 2021; 22(1): 47.
[http://dx.doi.org/10.1186/s40360-021-00513-x] [PMID: 34462002]
[7]
Xie H, Chen H, Hu Y, et al. Clindamycin-induced acute kidney injury: Large biopsy case series. Am J Nephrol 2013; 38(3): 179-83.
[http://dx.doi.org/10.1159/000354088] [PMID: 23941896]
[8]
Subedi P, Chowdhury A, Tanovic K, Dumic I. Clindamycin: An unusual cause of acute kidney injury. Am J Case Rep 2019; 20: 248-51.
[http://dx.doi.org/10.12659/AJCR.913779] [PMID: 30799434]
[9]
Egberts ACG, Meyboom RHB, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: Three Dutch examples. Drug Saf 2002; 25(6): 453-8.
[http://dx.doi.org/10.2165/00002018-200225060-00010] [PMID: 12071783]
[10]
Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18(6): 427-36.
[http://dx.doi.org/10.1002/pds.1742] [PMID: 19358225]
[11]
Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr. Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract 2021; 9(2): 819-29.
[http://dx.doi.org/10.1016/j.jaip.2020.09.021] [PMID: 32992044]
[12]
Böhm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol 2021; 87(11): 4421-31.
[http://dx.doi.org/10.1111/bcp.14868] [PMID: 33871897]
[13]
Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis 2020; 27(1): 31-7.
[http://dx.doi.org/10.1053/j.ackd.2019.08.001] [PMID: 32146999]
[14]
Wan H, Hu Z, Wang J, Zhang S, Yang X, Peng T. Clindamycin induced kidney diseases: A retrospective analysis of 50 patients. Intern Med 2016; 55(11): 1433-7.
[http://dx.doi.org/10.2169/internalmedicine.55.6084] [PMID: 27250048]
[15]
Katsuhara Y, Ikeda S. Correlations between SGLT-2 inhibitors and acute renal failure by signal detection using FAERS: Stratified analysis for reporting country and concomitant drugs. Clin Drug Investig 2021; 41(3): 235-43.
[http://dx.doi.org/10.1007/s40261-021-01006-9] [PMID: 33564981]
[16]
Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf 2020; 19(11): 1505-11.
[http://dx.doi.org/10.1080/14740338.2020.1799975] [PMID: 32693646]
[17]
Colilla S, Tov EY, Zhang L, et al. Validation of new signal detection methods for web query log data compared to signal detection algorithms used with FAERS. Drug Saf 2017; 40(5): 399-408.
[http://dx.doi.org/10.1007/s40264-017-0507-4] [PMID: 28155198]
[18]
Napoli AA, Wood JJ, Coumbis JJ, Soitkar AM, Seekins DW, Tilson HH. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc 2014; 17(1): 19214.
[http://dx.doi.org/10.7448/IAS.17.1.19214] [PMID: 25192857]
[19]
Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers 2020; 12(4): 826.
[http://dx.doi.org/10.3390/cancers12040826] [PMID: 32235443]
[20]
Patek TM, Teng C, Kennedy KE, Alvarez CA, Frei CR. Comparing acute kidney injury reports among antibiotics: A pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf 2020; 43(1): 17-22.
[http://dx.doi.org/10.1007/s40264-019-00873-8] [PMID: 31691256]
[21]
Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78(6): 743-50.
[PMID: 18819242]

Rights & Permissions Print Cite
Article Metrics
36
2
© 2024 Bentham Science Publishers | Privacy Policy